BB Biotech AG Added to SIX Swiss Exchange SPI ESG Index

BB Biotech AG has been included in the SPI ESG Index of the SIX Swiss Exchange effective September 22, 2025. This development recognizes the investment company's sustained dedication to responsible investing practices and sustainable corporate governance frameworks. The inclusion serves as external validation of BB Biotech's strategic orientation toward biotechnology companies that generate financial returns while contributing positively to societal healthcare needs.

Dr. Christian Koch, Head of BB Biotech at Bellevue Asset Management, emphasized the significance of this milestone, stating that the index inclusion confirms the company's commitment to sustainability principles. He further noted that this recognition underscores BB Biotech's strategic focus on identifying biotechnology firms that create shareholder value while addressing important medical challenges. The company's investment philosophy aligns with growing investor demand for portfolios that balance financial performance with positive social impact.

The SPI ESG Index, launched in 2021, comprises companies from the Swiss Performance Index that meet rigorous sustainability criteria as evaluated by independent agency Inrate. This selection process provides investors with a transparent benchmark for sustainable equity investments within the Swiss market. The index methodology ensures that included companies demonstrate strong environmental, social, and governance practices, offering market participants a reliable tool for identifying responsible investment opportunities. Additional information about the company's approach can be found at https://www.bbbiotech.com.

This inclusion carries significant implications for BB Biotech's market positioning and investor appeal. The enhanced visibility among ESG-oriented investors could potentially attract new capital from institutions and individuals prioritizing sustainable investment criteria. As one of the world's largest investors in the biotechnology sector, BB Biotech's recognition in the SPI ESG Index may influence industry standards for sustainable investing practices within healthcare-focused investment vehicles.

The timing of this development coincides with increasing global emphasis on ESG factors in investment decision-making. For biotechnology investors specifically, this inclusion provides additional confidence in BB Biotech's long-term strategic direction and portfolio construction methodology. The recognition may also strengthen the company's ability to engage with portfolio companies on sustainability matters, potentially influencing corporate practices across the biotechnology sector. The original announcement detailing this development is available at https://www.newmediawire.com.

BB Biotech's portfolio consists of innovative drug developers primarily headquartered in the United States and Western Europe, with investment decisions made by Bellevue Asset Management's experienced team based on comprehensive research. The company's inclusion in the SPI ESG Index reflects the growing intersection between biotechnology innovation and sustainable investment principles, potentially setting a benchmark for how healthcare-focused investment companies can align financial objectives with broader societal benefits.